Frost & Sullivan has recently completed an analysis of the market for the diagnosis of patients with acute kidney injury and on that basis acclaimed BioPorto and the NGAL test as a leader in the diagnosis of acute kidney injury.
BioPorto Diagnostics had identified an early biomarker known as neutrophil gelatinase-associated lipocalin (NGAL) to determine the risk of developing acute kidney injury or show progression of the condition significantly earlier (up to 48-72 hours) than other diagnostic tests in standard use today by hospitals and clinics. Using The NGAL Test can reduce the risks created by acute kidney injury in patients following, for example, heart surgery or a kidney transplant.
Frost & Sullivan highlights that The NGAL test in particular, because unlike competing assays it is developed to diagnose acute kidney injury in both blood and urine tests, and the NGAL Test is the only assay that can be used in a wide range of analytical instruments. This makes it easier for hospitals and clinics to implement a diagnostic test for acute kidney injury and thus achieve faster diagnosis.
BioPorto Diagnostics' CEO, Peter Morch Eriksen, is pleased and proud on behalf of the company receiving the award.
"Our mission is to help improve the diagnosis of patients at risk of developing acute kidney injury and improve the treatment of patients with acute kidney injury. Acute kidney injury has evolved to become a global burden, with millions affected by it and causing a proportional number of deaths each year. In most cases, acute kidney injury is detected too late and there is an acute and clear need for early diagnosis, so the disease can be prevented or treated quickly. "
"In the past few years several clinical studies have shown NGAL to be a biomarker that may help to save lives and improve the treatment of patients with AKI or at risk of developing AKI. Frost & Sullivan’s acclaim emphasizes that the NGAL Test is a product that can satisfy unmet needs in the health sector and thus make a difference to patients and doctors worldwide", added Mr. Eriksen.
Download the Frost & Sullivan report here.
For further information, please contact:
Peter Mørch Eriksen, CEO
Telephone 45 29 00 00, mail investor@bioporto.com
The kidney biomarker NGAL
Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock exchange.
